|
DK1202736T3
(da)
*
|
1999-07-28 |
2008-12-15 |
Univ Leland Stanford Junior |
Nikotin i terapeutisk angiogenese og vasculogenese
|
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
EP1381603A2
(en)
|
2000-08-18 |
2004-01-21 |
PHARMACIA & UPJOHN COMPANY |
Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
|
|
US6486172B2
(en)
|
2000-08-18 |
2002-11-26 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
WO2002015662A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
|
|
AU2001282875A1
(en)
|
2000-08-21 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
US20050130990A1
(en)
*
|
2001-03-23 |
2005-06-16 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
CA2341952A1
(en)
*
|
2001-03-23 |
2002-09-23 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
|
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
|
WO2003018585A1
(en)
|
2001-08-24 |
2003-03-06 |
Pharmacia & Upjohn Company |
Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
|
JP2005504059A
(ja)
*
|
2001-08-24 |
2005-02-10 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
|
|
DE60218493D1
(de)
*
|
2001-09-12 |
2007-04-12 |
Pharmacia & Upjohn Co Llc |
Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
|
|
SK1562004A3
(sk)
|
2001-10-02 |
2005-05-05 |
Pharmacia & Upjohn Company |
Azabicyklické substituované anelované heteroarylové zlúčeniny na liečenie chorôb
|
|
US6919359B2
(en)
*
|
2001-11-08 |
2005-07-19 |
Pfizer Inc |
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
|
|
JP2005510523A
(ja)
|
2001-11-09 |
2005-04-21 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
|
|
NZ554913A
(en)
*
|
2001-12-14 |
2009-01-31 |
Targacept Inc |
Methods and compositions for the treatment of central nervous system disorders
|
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
|
US6852741B2
(en)
*
|
2001-12-31 |
2005-02-08 |
University Of Florida |
Compositions and methods for treatment of neurological disorders
|
|
EP1480977A2
(en)
|
2002-02-15 |
2004-12-01 |
PHARMACIA & UPJOHN COMPANY |
Substituted aryl compounds for treatment of disease
|
|
US6858613B2
(en)
*
|
2002-02-19 |
2005-02-22 |
Pfizer Inc. |
Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
|
|
BR0307782A
(pt)
*
|
2002-02-19 |
2005-01-04 |
Upjohn Co |
Compostos azabiciclo para o tratamento de doença
|
|
JP2005525357A
(ja)
*
|
2002-02-20 |
2005-08-25 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
α７ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
|
|
US8557804B2
(en)
|
2002-03-25 |
2013-10-15 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
US8039459B2
(en)
*
|
2004-07-15 |
2011-10-18 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
AU2003253686A1
(en)
*
|
2002-08-01 |
2004-02-23 |
Pharmacia & Upjohn Company Llc |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
|
US7244745B2
(en)
*
|
2002-08-30 |
2007-07-17 |
Memory Pharmaceuticals Corp. |
Heterocyclic compounds, methods for the preparation thereof, and uses thereof
|
|
EP1562959A2
(en)
*
|
2002-11-01 |
2005-08-17 |
Pharmacia & Upjohn Company LLC |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
|
DE10251963A1
(de)
|
2002-11-08 |
2004-05-19 |
Lts Lohmann Therapie-Systeme Ag |
Transmucosale pharmazeutische Darreichungsform
|
|
EP1949901B1
(en)
*
|
2002-12-06 |
2014-02-12 |
The Feinstein Institute for Medical Research |
A method for determining a cholinergic agonist selective for an alpha 7 nicotinic receptor
|
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
|
WO2005023942A2
(en)
*
|
2003-02-20 |
2005-03-17 |
University Of Florida |
Materials and methods for inhibiting fouling of surfaces exposed to aquatic environments
|
|
US8580842B2
(en)
*
|
2003-09-30 |
2013-11-12 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
|
AU2005225458B2
(en)
|
2004-03-25 |
2008-12-04 |
The Feinstein Institutes For Medical Research |
Neural tourniquet
|
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
|
US20050288333A1
(en)
*
|
2004-06-08 |
2005-12-29 |
Kem William R |
Controlling angiogenesis with anabaseine analogs
|
|
CN102793972A
(zh)
|
2004-12-27 |
2012-11-28 |
范因斯坦医学研究院 |
通过电刺激迷走神经治疗炎症性疾病
|
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
|
US8093269B2
(en)
|
2005-06-07 |
2012-01-10 |
University Of Florida Research Foundation |
Alpha 7 nicotinic receptor selective ligands
|
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
|
US7662965B2
(en)
|
2006-01-26 |
2010-02-16 |
Cornerstone Therapeutics, Inc. |
Anabaseine derivatives, pharmaceutical compositions and method of use thereof
|
|
US20080167286A1
(en)
|
2006-12-12 |
2008-07-10 |
Abbott Laboratories |
Pharmaceutical compositions and their methods of use
|
|
US8486979B2
(en)
*
|
2006-12-12 |
2013-07-16 |
Abbvie Inc. |
1,2,4 oxadiazole compounds and methods of use thereof
|
|
UY30846A1
(es)
|
2006-12-30 |
2008-07-31 |
Abbott Gmbh & Amp |
Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
|
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
|
US8703774B2
(en)
|
2007-12-07 |
2014-04-22 |
AbbVie Deutschland GmbH & Co. KG |
Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
|
|
EP2623504A1
(de)
*
|
2007-12-07 |
2013-08-07 |
Abbott GmbH & Co. KG |
5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
|
|
ES2398676T3
(es)
*
|
2007-12-07 |
2013-03-20 |
Abbott Gmbh & Co. Kg |
Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
|
|
KR20100097195A
(ko)
*
|
2007-12-07 |
2010-09-02 |
애보트 게엠베하 운트 콤파니 카게 |
５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
|
|
US8383657B2
(en)
|
2007-12-21 |
2013-02-26 |
Abbott Laboratories |
Thiazolylidine urea and amide derivatives and methods of use thereof
|
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
|
WO2009146031A1
(en)
*
|
2008-03-31 |
2009-12-03 |
University Of South Florida |
Methods of treating disease-induced ataxia and non-ataxic imbalance
|
|
US9211409B2
(en)
|
2008-03-31 |
2015-12-15 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of T-cell activity
|
|
ES2452484T3
(es)
|
2008-11-18 |
2014-04-01 |
Setpoint Medical Corporation |
Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
|
|
KR20140146216A
(ko)
|
2008-11-19 |
2014-12-24 |
포럼 파마슈티칼즈 인크. |
(ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
PE20120324A1
(es)
*
|
2009-05-11 |
2012-04-17 |
Envivo Pharmaceuticals Inc |
Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
|
|
WO2010138600A2
(en)
|
2009-05-29 |
2010-12-02 |
Abbott Laboratories |
Pharmaceutical compositions for the treatment of pain
|
|
EP2440284B1
(en)
|
2009-06-09 |
2018-09-12 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
|
WO2014169145A1
(en)
|
2013-04-10 |
2014-10-16 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
|
WO2011079309A2
(en)
|
2009-12-23 |
2011-06-30 |
Setpoint Medical Corporation |
Neural stimulation devices and systems for treatment of chronic inflammation
|
|
MY165234A
(en)
|
2010-05-17 |
2018-03-14 |
Forum Pharmaceuticals Inc |
A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
|
|
WO2012031220A2
(en)
|
2010-09-03 |
2012-03-08 |
University Of Florida Research Foundation, Inc. |
Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
|
|
US12172017B2
(en)
|
2011-05-09 |
2024-12-24 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
WO2012154865A2
(en)
|
2011-05-09 |
2012-11-15 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
|
US9585877B2
(en)
|
2012-05-08 |
2017-03-07 |
Forum Pharmaceuticals, Inc. |
Methods of maintaining, treating or improving cognitive function
|
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
|
WO2017127758A1
(en)
|
2016-01-20 |
2017-07-27 |
Setpoint Medical Corporation |
Implantable microstimulators and inductive charging systems
|
|
CN114904142A
(zh)
|
2016-01-20 |
2022-08-16 |
赛博恩特医疗器械公司 |
迷走神经刺激的控制
|
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
|
WO2018064529A1
(en)
|
2016-09-29 |
2018-04-05 |
The Uab Research Foundation |
Methods and compositions for increasing mucus clearance
|
|
EP3668402B1
(en)
|
2017-08-14 |
2024-07-31 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
|
EP3806956A4
(en)
|
2018-06-13 |
2022-08-10 |
Zachriel Neurosciences, Llc |
METHODS AND DOSAGE REGIMES FOR PREVENTING OR DELAYING THE ONSET OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT
|
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
|
AU2020272128B9
(en)
|
2019-04-12 |
2025-11-20 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
US12533531B2
(en)
|
2020-01-13 |
2026-01-27 |
The Feinstein Institutes For Medical Research |
Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
|
|
IL304787B2
(en)
|
2020-05-21 |
2025-12-01 |
Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|
|
WO2021249608A2
(en)
*
|
2020-06-09 |
2021-12-16 |
Elkazaz Mohamed Fadly Abd El Ghany |
A novel medicament for immune modulation and treating chronic or hyper inflammation
|
|
WO2022245878A1
(en)
|
2021-05-17 |
2022-11-24 |
Setpoint Medical Corporation |
Neurostimulation parameter authentication and expiration system for neurostimulation
|